Does it work and should he take it are separate questions, and the NU553 Unit 1 post answers the second for a composite 66-year-old using the 2022 USPSTF statement. Searches like "nu 553 unit 1 assignment example", "nu553 unit 1 sample" and "nu553 unit 1 example" land here.
Aspirin Works, but Should He Start It? A Dated No for a 66-Year-Old With a 14 Percent Risk
NU553 · Unit 1 Discussion
Posted by [Student Name]
The patient is a composite; no real person is described.
Initial Post
Two questions are easy to run together here. The first is whether aspirin reduces cardiovascular events in people without known vascular disease. It does, modestly: by inhibiting cyclooxygenase-1 in platelets irreversibly, low-dose aspirin blocks thromboxane A2 production for the life of each platelet, and trials show fewer first myocardial infarctions in people who take it. The second question is whether Mr. [J.], 66, should start it. That a drug works on average does not settle whether its benefit outweighs its harm in one person at his age and risk.
The same mechanism that prevents clots causes bleeding. Aspirin increases gastrointestinal bleeding and, less often, intracranial hemorrhage, and the risk of bleeding rises with age. In older trials, the benefit in preventing first events was large enough to justify aspirin in many adults. In more recent trials, with better blood pressure and cholesterol treatment in the background, the benefit shrank while the bleeding risk stayed. In ASPREE, a trial of healthy adults mostly aged 70 and older, aspirin did not reduce cardiovascular disease meaningfully and increased major hemorrhage (McNeil et al., 2018).
My answer for Mr. [J.] is no, as of September 2026. Current federal guidance recommends against starting low-dose aspirin for primary prevention in adults aged 60 or older, because the net benefit is zero or negative (US Preventive Services Task Force, 2022). His 14 percent risk would have made him a candidate for individual discussion if he were 55; at 66, age tips the balance toward bleeding. His blood pressure control, a statin if he is not taking one, and smoking status if relevant will do more for his risk with less harm.
I have dated the answer on purpose. This recommendation reversed earlier guidance, and it may change again as evidence accumulates. A no based on current trials is the honest answer now; it is not a claim that aspirin never helps.
Reply to Danielle
Danielle, you said you would start aspirin for your 58-year-old patient with diabetes and a 12 percent risk. Under the same guidance, that is a shared decision rather than a no, so I think your answer can stand. What bleeding history did you ask about first? I would want to know about ulcers and anticoagulant use before I raised it with him.
References
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., Shah, R. C., Williamson, J. D., Margolis, K. L., Ernst, M. E., Abhayaratna, W. P., Stocks, N., Fitzgerald, S. M., Orchard, S. G., Trevaks, R. E., ... Murray, A. M. (2018). Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. New England Journal of Medicine, 379(16), 1509-1518. https://doi.org/10.1056/NEJMoa1805819
US Preventive Services Task Force. (2022). Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA, 327(16), 1577-1584. https://doi.org/10.1001/jama.2022.4983
How this NU553 Unit 1 example is structured
The post rests on a distinction the course returns to often, between pharmacology and therapeutics, and it makes the distinction visible by giving each its own paragraph. Mechanism and efficacy are granted in full, so the refusal cannot be mistaken for doubt about the drug. The decision paragraph weighs benefit against harm in this man, using his age and risk figure, and treats the Task Force grade as a dated summary of evidence rather than a rule that ends thought. Its limits are named: ASPREE enrolled people mostly 70 and older, so it supports the direction of the argument more than its exact threshold. The plan paragraph does what the prompt's framing asks, attaching a goal and a review date to the therapy he should have. One reply question invites a classmate to say where their own age threshold would sit.
Get an NU553 Unit 1 example written to your instructions
The Unit 1 board question from your NU553 section, pasted as written, together with the grading criteria and whatever patient details the prompt gives, is enough to begin. No charge applies to a first post, which returns in 24-48h, grants what the drug does, decides whether this particular patient ought to start it, and dates every guideline it relies on. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU553 Unit 1 questions, answered
Can a post argue against a drug that clearly works?
Yes, and the first NU553 board often invites exactly that. A drug can do what it claims and still be wrong for a particular patient because of age, bleeding risk, other medicines or goals. The stronger posts grant the efficacy first, then show which of the patient's details tips the balance, and cite a dated source for the threshold used.
Which USPSTF statement applies to someone in their fifties?
The 2022 statement treats adults 40 to 59 whose 10-year cardiovascular risk sits at or above 10 percent as an individual decision, a grade C, because the net benefit is small. Posts about younger patients usually discuss bleeding risk and preferences before recommending anything, and they still date the source, since the Task Force has revised this topic more than once.
Should the post include a risk calculator result?
If the case provides one, use it and name the tool, typically the pooled cohort equations or the newer PREVENT equations the American Heart Association released in 2023. If the case does not, the post can note that the decision depends on it. A risk figure without the tool behind it is hard for a grader to check.